Skip to main content
. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044

Figure 4.

Figure 4

Meta-analysis and TSA results of blood pressure-related indicators in dorzagliatin vs. placebo in the treatment of T2DM. (A) Meta-analysis and TSA results of SBP in dorzagliatin vs. placebo in the treatment of T2DM. (B) Meta-analysis and TSA results of DBP in dorzagliatin vs. placebo in the treatment of T2DM.